Related Experiment Video
Updated: Jan 22, 2026
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
2.2K
Nivo-lution in Mesothelioma
Aaron S Mansfield1, Marjorie G Zauderer2
1Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. mansfield.aaron@mayo.edu.
Summary
The MERIT trial demonstrated that nivolumab, a PD-1 inhibitor, is effective for malignant pleural mesothelioma. This finding supported the approval of nivolumab for treating this cancer in Japan.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Malignant pleural mesothelioma is a rare and aggressive cancer.
- Limited effective treatment options exist for advanced mesothelioma.
Purpose of the Study:
- To evaluate the efficacy of nivolumab in patients with malignant pleural mesothelioma.
- To assess PD-1 inhibition activity in this patient population.
Main Methods:
- Single-arm, phase II clinical trial (MERIT study).
- Nivolumab administered as second- or third-line treatment.
- Conducted in patients in Japan.
Main Results:
- Nivolumab demonstrated clinical activity in malignant pleural mesothelioma.
- The study confirmed the benefit of PD-1 inhibition.
Conclusions:
- Nivolumab is an effective treatment for malignant pleural mesothelioma.
- The MERIT study led to regulatory approval of nivolumab in Japan.
